Health Catalyst, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on January 20, 2026. The report discloses a significant change in executive leadership regarding the Chief Commercial Officer role.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and related compensatory arrangements.
Material Changes
- Executive Departure: Kevin Freeman will cease serving as Chief Commercial Officer effective February 1, 2026.
- Transition Role: Mr. Freeman is expected to enter an independent contractor agreement to serve as a senior advisor starting February 2, 2026.
- Compensation: A separation agreement will provide benefits under the Company's Executive Severance Plan in exchange for a general release of claims.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the execution of the separation and contractor agreements. Management notes that actual results may differ materially due to risks and uncertainties disclosed in recent Form 10-K and 10-Q filings. The Company does not intend to update these statements except as required by law.
Investor Verification Checklist
- Verify the terms of the Executive Severance Plan referenced in the Definitive Proxy Statement (Schedule 14A) filed on May 19, 2025.
- Confirm the final terms of the independent contractor agreement for the senior advisor role.
- Review the Company's most recent Form 10-K for broader risk factors related to executive turnover.
- Monitor subsequent filings for the appointment of a permanent replacement for the Chief Commercial Officer.